Search

Your search keyword '"NUNNARI, G."' showing total 802 results
Start Over Author "NUNNARI, G."
802 results on '"NUNNARI, G."'

102. Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study

Author

Leone, S., Lorenzini, P., Cozzi-Lepri, A., Orofino, G., Bernacchia, D., Castagna, A., Menozzi, M., Guaraldi, G., Madeddu, G., Di Biagio, A., Puoti, M., Gori, A., d'Arminio Monforte, A, Cacopardo, B, B M, Celesia, Nunnari, G, Leone, S, Lorenzini, P, Cozzi-Lepri, A, Orofino, G, Bernacchia, D, Castagna, A, Menozzi, M, Guaraldi, G, Madeddu, G, Di Biagio, A, Puoti, M, Gori, A, d'Arminio Monforte, A, Leone, S., Lorenzini, P., Cozzi-Lepri, A., Orofino, G., Bernacchia, D., Castagna, A., Menozzi, M., Guaraldi, G., Madeddu, G., Di Biagio, A., Puoti, M., Gori, A., and d'Arminio Monforte, A.

Subjects
0301 basic medicine, Liver Cirrhosis, Male, Human immunodeficiency virus (HIV), HIV Infections, medicine.disease_cause, HIV/HCV co-infection . Serious liver events . Liver-related deaths . Diabetes mellitus, 0302 clinical medicine, Medical microbiology, Diabetes mellitus, 80 and over, 030212 general & internal medicine, Prospective Studies, Chronic, Aged, 80 and over, education.field_of_study, Coinfection, Incidence, virus diseases, General Medicine, Hepatitis C, Middle Aged, Infectious Diseases, Female, Cohort study, Microbiology (medical), Adult, medicine.medical_specialty, Diabetes mellitu, HIV/HCV co-infection, Liver-related deaths, Serious liver events, Aged, Diabetes Complications, Hepatitis C, Chronic, Humans, Liver Failure, Risk Assessment, Survival Analysis, 030106 microbiology, Population, Liver-related death, NO, 03 medical and health sciences, Internal medicine, medicine, education, Serious liver event, business.industry, medicine.disease, Hiv patients, business, Co infection
Abstract

To investigate the association between diabetes and HCV infection in persons living with HIV and to determine the impact of diabetes on the occurrence of serious liver events (SLEs) and liver-related deaths (LRDs) among HIV/HCV-co-infected patients. Patients were included if they had at least one follow-up visit. In a cross-sectional analysis among all HIV patients, we have investigated the association between diabetes and HCV infection. A further longitudinal analysis was performed in the population of HIV/HCV-co-infected free from SLE with FIB-4 index < 3.25 at baseline, using the following endpoints: (A) first event between SLE and LRD; (B) liver fibrosis progression defined as the first of two consecutive FIB-4 > 3.25; (C) first event between SLE, LRD, and liver fibrosis progression. Data from 15,571 HIV patients were analyzed: 2944 (18.9%) were HCV-Ab positive, and 739 (4.7%) presented a diagnosis of diabetes at their last follow-up. Among HIV/HCV-co-infected population, 107 patients had a diagnosis of diabetes. Viremic HCV-co-infected patients had 3-fold risk of diabetes onset than HCV-uninfected patients. On HIV/HCV-co-infected population, 85 SLEs/LRDs occurred over 20,410 person-years of follow-up (PYFU), for an incidence rate of 4.2/1000 PYFU (95%CI 3.4–5.2). Diabetic patients had 3-fold risk of pooled SLE and LRD than patients without diabetes. Furthermore, viremic HCV infection was independently associated with a higher risk of SLE/LRD (aIRR 3.35 [95%CI 1.14–9.83]). In HIV-infected patients, viremic HCV co-infection is a strong predictor of diabetes. Among HIV/HCV-co-infected population, diabetic patients showed an increased risk of SLE/LRD compared with those without diabetes.

Published
2019

106. Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudina/Dolutegravir Therapy in Human Immunodeficiency Virus Treatment-Experienced Patients

Author

Olearo, F., Nnguyen, H., Bonnet, F., Yerly, S., Wander, G., Stoexkle, M., Cavassini, M., Scherrer, A., Costagliola, D., Schmid, P., Gunthard, H. F., Bernasconi, E., Boeni, J., D’Arminio Monforte, A., Zazzi, M., Rossetti, B., Neau, D., Bellecave, P., Rijnders, B., Reiss, P., Wit, F., Kouyos, R., Calmy, A., we acknowledge member of the ICONA Group, Nunnari, G., and Pellicanò, G. F.

Subjects
virological failure, ABC/3TC/DTG, ABC/3TC/DTG, virological failure, M184V/I, treatment-experienced patients, treatment-experienced patients, M184V/I
Published
2019

111. Comparative neuropsychiatric toxicity profile of dolutegravir versus efavirenz versus other antiretroviral third drugs used either in first-line or switching antiretroviral therapies (ART): data from ICONA Foundation Study Cohort

Author

Mondi, A., Cozzi-Lepri, A., Cingolani, A., Tavelli, A., Puoti, M., Barocci, V., Londero, A., Bai, F., Pinnetti, C., Cinque, P., d’Arminio Monforte, A., Antinori on behalf of ICONA Foundation Study Group, A., Nunnari, G., and G. F. Pellicanò.

Published
2019

116. Parallel simulation of cellular neural networks

Author

Fortuna, L., Manganaro, G., Muscato, G., and Nunnari, G.

Subjects
Neural networks -- Research, Parallel processing -- Research, Simulation methods -- Research, Transputers -- Research, Computers, Electronics, Engineering and manufacturing industries
Abstract

In this paper a new simulator for cellular neural networks (CNN) called PSIMCNN is presented. It has been studied for a parallel general-purpose computing architecture based on transputers. The Gauss-Jacobi waveform relaxation (WR) algorithm has been adopted. It has been analytically proved that the WR algorithm is convergent for the most common CNN models. Implementation issues have been described and some experimental results comprising classical CNN and Chua circuits CNN simulations have been presented. Parallelism and performances have been investigated. Moreover, a comparison with the CNN-HAC simulator is reported. Key words: Cellular neural networks, simulators, non-linear circuits, transputer, parallel processing.

Published
1996

117. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort

Author

Mondi, A., Cozzi-Lepri, A., Tavelli, A., Rusconi, S., Vichi, F., Ceccherini-Silberstein, F., Calcagno, A., De Luca, A., Maggiolo, F., Marchetti, G., Antinori, A., d'Arminio Monforte, A., Andreoni, M., Castagna, A., Castelli, F., Cauda, Roberto, Di Perri, G., Galli, M., Iardino, R., Ippolito, Giuseppe, Azzarin, A., Rezza, Giovanni, von Schloesser, F., Viale, P., Girardi, E., Lo Caputo, S., Mussini, C., Puoti, M., Perno, C. F., Balotta, C., Bandera, A., Bonora, S., Borderi, M., Capetti, A., Capobianchi, M. R., Cicalini, S., Cingolani, Antonella, Cinque, P., Di Biagio, Anna, Gianotti, N., Gori, A., Guaraldi, G., Lapadula, G., Lichtner, M., Madeddu, G., Monno, L., Nozza, S., Quiros Roldan, E., Rossotti, R., Santoro, M. M., Aracino, A., Sarmati, L., Fanti, I., Lorenzini, P., Rodano', A., Macchia, M., Carletti, F., Carrara, S., Di Caro, A., Graziano, S., Petrone, F., Prota, G., Quartu, S., Truffa, S., Giacometti, I. A., Costantini, A., Barocci, V., Angarano, G., Fabrizio, C., Suardi, C., I, V., Verucchi, G., Castelnuovo, F., Minardi, C., Menzaghi, B., Abeli, C., Cacopardo, Beatrice Marina, Celesia, B., Vecchiet, J., Falasca, K., Pan, A., Lorenzotti, S., Sighinolfi, L., Segala, D., Blanc, P., Cassola, G., Viscoli, C., Lessandrini, A., Bobbio, N., Mazzarello, G., Pozzetto, I., Bonfanti, P., Molteni, C., Chiodera, A., Milini, P., Nunnari, G., Pellicano, G., Rizzardini, G., Bai, F., Moioli, M. C., Piolini, R., Ridolfo, A. L., Salpietro, S., Tincati, C., Puzzolante, C., Migliorino, C., Sangiovanni, V., Borgia, G., Esposito, V., Di Martino, F., Gentile, I., Maddaloni, L., Cattelan, A. M., Marinello, S., Cascio, A., Colomba, C., Baldelli, F., Schiaroli, E., Parruti, G., Sozio, F., Magnani, G., Ursitti, M. A., Cristaudo, A., Vullo, V., Acinapura, R., Baldin, G., Capozzi, M., Rivano Capparucia, M., Iaiani, G., Atini, A., Mastrorosa, I., Plazzi, M. M., Savinelli, S., Vergori, A., Cecchetto, M., Viviani, F., Bagella, P., Rossetti, Barbara, Fontana Del Vecchio, R., Francisci, D., Di Giuli, C., Caramello, P., Orofino, G. C., Sciandra, M., Bassetti, M., Ondero, A., Pellizzer, G., Manfrin, V., Starnini, G., Alungo, A., Cauda R. (ORCID:0000-0002-1498-4229), Ippolito G., Rezza G., Cingolani A. (ORCID:0000-0002-3793-2755), Di Biagio A., Cacopardo B., Rossetti B., Mondi, A., Cozzi-Lepri, A., Tavelli, A., Rusconi, S., Vichi, F., Ceccherini-Silberstein, F., Calcagno, A., De Luca, A., Maggiolo, F., Marchetti, G., Antinori, A., d'Arminio Monforte, A., Andreoni, M., Castagna, A., Castelli, F., Cauda, Roberto, Di Perri, G., Galli, M., Iardino, R., Ippolito, Giuseppe, Azzarin, A., Rezza, Giovanni, von Schloesser, F., Viale, P., Girardi, E., Lo Caputo, S., Mussini, C., Puoti, M., Perno, C. F., Balotta, C., Bandera, A., Bonora, S., Borderi, M., Capetti, A., Capobianchi, M. R., Cicalini, S., Cingolani, Antonella, Cinque, P., Di Biagio, Anna, Gianotti, N., Gori, A., Guaraldi, G., Lapadula, G., Lichtner, M., Madeddu, G., Monno, L., Nozza, S., Quiros Roldan, E., Rossotti, R., Santoro, M. M., Aracino, A., Sarmati, L., Fanti, I., Lorenzini, P., Rodano', A., Macchia, M., Carletti, F., Carrara, S., Di Caro, A., Graziano, S., Petrone, F., Prota, G., Quartu, S., Truffa, S., Giacometti, I. A., Costantini, A., Barocci, V., Angarano, G., Fabrizio, C., Suardi, C., I, V., Verucchi, G., Castelnuovo, F., Minardi, C., Menzaghi, B., Abeli, C., Cacopardo, Beatrice Marina, Celesia, B., Vecchiet, J., Falasca, K., Pan, A., Lorenzotti, S., Sighinolfi, L., Segala, D., Blanc, P., Cassola, G., Viscoli, C., Lessandrini, A., Bobbio, N., Mazzarello, G., Pozzetto, I., Bonfanti, P., Molteni, C., Chiodera, A., Milini, P., Nunnari, G., Pellicano, G., Rizzardini, G., Bai, F., Moioli, M. C., Piolini, R., Ridolfo, A. L., Salpietro, S., Tincati, C., Puzzolante, C., Migliorino, C., Sangiovanni, V., Borgia, G., Esposito, V., Di Martino, F., Gentile, I., Maddaloni, L., Cattelan, A. M., Marinello, S., Cascio, A., Colomba, C., Baldelli, F., Schiaroli, E., Parruti, G., Sozio, F., Magnani, G., Ursitti, M. A., Cristaudo, A., Vullo, V., Acinapura, R., Baldin, G., Capozzi, M., Rivano Capparucia, M., Iaiani, G., Atini, A., Mastrorosa, I., Plazzi, M. M., Savinelli, S., Vergori, A., Cecchetto, M., Viviani, F., Bagella, P., Rossetti, Barbara, Fontana Del Vecchio, R., Francisci, D., Di Giuli, C., Caramello, P., Orofino, G. C., Sciandra, M., Bassetti, M., Ondero, A., Pellizzer, G., Manfrin, V., Starnini, G., Alungo, A., Cauda R. (ORCID:0000-0002-1498-4229), Ippolito G., Rezza G., Cingolani A. (ORCID:0000-0002-3793-2755), Di Biagio A., Cacopardo B., and Rossetti B.

Abstract

Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to estimate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected individuals. Methods: We performed a multicentre, observational study including all antiretroviral therapy (ART)-naïve and virologically suppressed treatment-experienced (TE) patients from the Icona (Italian Cohort Naïve Antiretrovirals) cohort who started, for the first time, a DTG-based regimen from January 2015 to December 2017. We estimated the cumulative risk of DTG discontinuation regardless of the reason and for toxicity, and of virological failure using Kaplan–Meier curves. We used Cox regression model to investigate predictors of DTG discontinuation. Results: About 1679 individuals (932 ART-naïve, 747 TE) were included. The one- and two-year probabilities (95% CI) of DTG discontinuation were 6.7% (4.9 to 8.4) and 11.5% (8.7 to 14.3) for ART-naïve and 6.6% (4.6 to 8.6) and 7.6% (5.4 to 9.8) for TE subjects. In both ART-naïve and TE patients, discontinuations of DTG were mainly driven by toxicity with an estimated risk (95% CI) of 4.0% (2.6 to 5.4) and 2.5% (1.3 to 3.6) by one year and 5.6% (3.8 to 7.5) and 4.0% (2.4 to 5.6) by two years respectively. Neuropsychiatric events were the main reason for stopping DTG in both ART-naïve (2.1%) and TE (1.7%) patients. In ART-naïve, a concomitant AIDS diagnosis predicted the risk of discontinuing DTG for any reason (adjusted relative hazard (aRH) = 3.38, p = 0.001), whereas starting DTG in combination with abacavir (ABC) was associated with a higher risk of discontinuing because of toxicity (aRH = 3.30, p = 0.009). TE patients starting a DTG-based dual therapy compared to a triple therapy had a lower risk of discontinuation for any reason (adjusted hazard ratio (aHR) = 2.50, p = 0.037 for ABC-based triple-th

Published
2019

118. Novelties in evaluation and monitoring of human immunodeficiency virus-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success?

Author

Svicher, V., Marchetti, G., Ammassari, A., Ceccherini-Silberstein, F., Sarmati, L., Andreoni, M., Angarano, G., Antinori, A., Antonelli, G., Bandera, A., Bonfanti, P., Bonora, S., Borderi, M., Calcagno, A., Capobianchi, M. R., Castagna, A., Castelli, F., Cauda, R., Celesia, B. M., Chirianni, A., Cicalini, S., Cingolani, A., Cinque, P., Clementi, M., Cossarizza, A., Monforte, A. D., D'Ettorre, G., De Luca, A., Di Biagio, A., Di Perri, G., Galli, M., Gianotti, N., Girardi, E., Guaraldi, G., Lazzarin, A., Lichtner, M., Lo Caputo, S., Madeddu, G., Maggi, P., Maggiolo, F., Marchetti, G. C., Mastroianni, C., Mussini, C., Nozza, S., Nunnari, G., Parisi, S., Parruti, G., Perno, C. F., Piconi, S., Carla, M., Ripamonti, D., Rusconi, S., Santoro, M., Sterrantino, G., Vullo, V., Zaccarelli, M., Zazzi, M., Svicher, V, Marchetti, G, Ammassari, A, Ceccherini-Silberstein, F, Sarmati, L, Andreoni, M, Angarano, G, Antinori, A, Antonelli, G, Bandera, A, Bonfanti, P, Bonora, S, Borderi, M, Calcagno, A, Capobianchi, M, Castagna, A, Castelli, F, Cauda, R, Celesia, B, Chirianni, A, Cicalini, S, Cingolani, A, Cinque, P, Clementi, M, Cossarizza, A, Monforte, A, D'Ettorre, G, De Luca, A, Di Biagio, A, Di Perri, G, Galli, M, Gianotti, N, Girardi, E, Guaraldi, G, Lazzarin, A, Lichtner, M, Lo Caputo, S, Madeddu, G, Maggi, P, Maggiolo, F, Mastroianni, C, Mussini, C, Nozza, S, Nunnari, G, Parisi, S, Parruti, G, Perno, C, Piconi, S, Carla, M, Ripamonti, D, Rusconi, S, Santoro, M, Sterrantino, G, Vullo, V, Zaccarelli, M, and Zazzi, M

Subjects
Inflammation, Genotypic resistance testing, HIV-DNA, Immune-activation, Low level viremia, Residual viremia
Abstract

The high potency and tolerability of the currently available antiretroviral drugs has modified HIV-1 infection from a life-threatening disease to a chronic illness. Nevertheless, some issues still remain open to optimize the management of HIV-1 infected patients in term of maintenance of virological suppression over time, identifying patients that could benefit from simplification therapy, and reducing co-mordibities driven by chronic inflammation. The availability of robust and affordable virological and immunological markers can help in solving these issues by providing information on the burden of HIV-1 reservoir in all the anatomical compartments in which the virus replicates as well as on persistent inflammation, immune activation and senescence despite successful virological suppression. In this light, this review is aimed at providing new insights (arising from a two-day Italian expert meeting hold in Rome in March 2016) in evaluation and monitoring of HIV-1 infection from a virological, immunological and clinical perspective. Particular attention has been focused on role of novel parameters (such as total HIV-1 DNA, residual viremia, and immunological markers) in optimizing treatment strategies, enhancing medical adherence, and individualizing monitoring.

Published
2017

119. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting

Author

Antonella d'Arminio Monforte, Alessandro, Cozzi-Lepri, DI BIAGIO, Antonio, Giulia, Marchetti, Sergio Lo Caputo, Stefano, Rusconi, Nicola, Gianotti, Valentina, Mazzotta, Giovanni, Mazzarello, Andrea, Costantini, Antonella, Castagna, Andrea, Antinori, A d'Arminio Monforte, Antinori, A, Andreoni, M, Castagna, A, Castelli, F, Cauda, R, G Di Perri, Galli, M, Iardino, R, Ippolito, G, Lazzarin, A, C Marchetti, G, Rezza, G, F von Schloesser, Viale, P, Ceccherini-Silberstein, F, Cozzi-Lepri, A, Girardi, E, S Lo Caputo, Mussini, C, Puoti, M, F Perno, C, Balotta, C, Bandera, A, Bonora, S, Borderi, M, Calcagno, A, Capetti, A, R Capobianchi, M, Cicalini, S, Cingolani, A, Cinque, P, A De Luca, A Di Biagio, Gianotti, N, Gori, A, Guaraldi, G, Lapadula, G, Lichtner, M, Madeddu, G, Maggiolo, F, Marchetti, G, Monno, L, Nozza, S, Pinnetti, C, E Quiros Roldan, Rossotti, R, Rusconi, S, M Santoro, M, Saracino, A, Sarmati, L, Fanti, I, Galli, L, Lorenzini, P, Rodan(`(o))', A, Macchia, M, Tavelli, A, Carletti, F, Carrara, S, A Di Caro, Graziano, S, Petrone, F, Prota, G, Quartu, S, Truffa, S, Giacometti, A, Costantini, A, Barocci, V, Angarano, G, Fabrizio, C, Suardi, C, Donati, V, Verucchi, G, Castelnuovo, F, Minardi, C, Menzaghi, B, Abeli, C, Cacopardo, B, Celesia, B, Vecchiet, J, Falasca, K, Pan, A, Lorenzotti, S, Sighinolfi, L, Segala, D, Blanc, P, Vichi, F, Cassola, G, Viscoli, C, Alessandrini, A, Bobbio, N, Mazzarello, G, Pozzetto, I, Bonfanti, P, Molteni, C, Chiodera, A, Milini, P, Nunnari, G, Pellican(`(o)), G, Rizzardini, G, Bai, F, C Moioli, M, Piolini, R, L Ridolfo, A, Salpietro, S, Tincati, C, Puzzolante, C, Migliorino, C, Sangiovanni, V, Borgia, G, Esposito, V, F Di Martino, Gentile, I, Maddaloni, L, M Cattelan, A, Marinello, S, Cascio, A, Colomba, C, Baldelli, F, Schiaroli, E, Parruti, G, Sozio, F, Magnani, G, A Ursitti, M, Cristaudo, A, Vullo, V, Acinapura, R, Baldin, G, Capozzi, M, Mondi, A, M Rivano Capparucia, Iaiani, G, Latini, A, Gagliardini, R, M Plazzi, M, Savinelli, S, Vergori, A, Cecchetto, M, Viviani, F, Bagella, P, Rossetti, B, Franco, A, R Fontana Del Vecchio, Francisci, D, C Di Giuli, Caramello, P, C Orofino, G, Sciandra, M, Bassetti, M, Londero, A, Pellizzer, G, Manfrin, V, Starnini, G, A Ialungo and, d'Arminio Monforte, Antonella, Cozzi-Lepri, Alessandro, Di Biagio, Antonio, Marchetti, Giulia, Lo Caputo, Sergio, Rusconi, Stefano, Gianotti, Nicola, Mazzotta, Valentina, Mazzarello, Giovanni, Costantini, Andrea, Castagna, Antonella, and Antinori, Andrea

Subjects
0301 basic medicine, Male, Integrase inhibitor, hiv, HIV Infections, Quinolones, Piperazines, Settore MED/07, Cohort Studies, chemistry.chemical_compound, 0302 clinical medicine, HIV Seropositivity, Pharmacology (medical), 030212 general & internal medicine, Treatment Failure, risk reduction, cd4 count, toxic effect, Elvitegravir, cox proportional hazards models, Cobicistat, hiv, cd4 count, determination procedure, hiv seropositivity, integrase inhibitors, plasma, treatment failure, virology, toxic effect, risk reduction, cox proportional hazards models, elvitegravir, raltegravir, surrogate endpoints, cobicistat, dolutegravir, time-to-treatment, Middle Aged, virology, dolutegravir, Infectious Diseases, integrase inhibitors, Italy, Dolutegravir, hiv,cd4 count determination procedure, hiv seropositivity, integrase inhibitors, plasma, treatment failure, virology, toxic effect, risk reduction, cox proportional hazards models, elvitegravir, raltegravir, surrogate endpoints, cobicistat, dolutegravir, time-to-treatment, elvitegravir, Regression Analysis, Female, raltegravir, Heterocyclic Compounds, 3-Ring, medicine.drug, Microbiology (medical), Adult, medicine.medical_specialty, Pyridones, 030106 microbiology, time-to-treatment, Lower risk, 03 medical and health sciences, Internal medicine, Raltegravir Potassium, Oxazines, medicine, Humans, HIV Integrase Inhibitors, plasma, Pharmacology, business.industry, Surrogate endpoint, Raltegravir, Survival Analysis, Discontinuation, CD4 Lymphocyte Count, chemistry, determination procedure, surrogate endpoints, business
Abstract

Objectives To evaluate the durability of three integrase strand transfer inhibitors (INSTIs) and two NRTIs in ART-naive individuals. Methods The study design was observational. Patients were HIV-positive, ART-naive subjects starting raltegravir, elvitegravir/cobicistat or dolutegravir with two NRTIs. The primary endpoint was time to treatment failure, i.e. occurrence of virological failure (first of two consecutive plasma HIV RNAs ≥200 copies/mL after 24 weeks) or INSTI discontinuation for any reason apart from simplification. Secondary endpoints were INSTI discontinuation due to toxicity/intolerance and CD4 count response. Survival analysis was done using Kaplan-Meier and Cox regression. Results Two thousand and sixteen patients were included: 310 (15.4%) started raltegravir-based regimens, 994 (49.3%) started dolutegravir-based regimens and 712 (35.3%) started elvitegravir/cobicistat-based regimens. Over a median of 11 months, 167 patients experienced treatment failure; the 1 year probability of treatment failure was 6.5% for raltegravir, 5.4% for dolutegravir and 6.7% for elvitegravir/cobicistat (P = 0.001). Sixty-eight patients (3.4%) discontinued INSTIs owing to toxicity/intolerance. By multivariable analysis, patients starting raltegravir had a 2.03-fold (95% CI = 1.2-3.2) higher risk and patients on elvitegravir/cobicistat a 1.88-fold (95% CI = 1.2-2.9) higher risk of treatment failure versus dolutegravir; there was no difference in risk of discontinuation due to toxicity/intolerance when comparing dolutegravir and raltegravir and marginal evidence for a difference when comparing elvitegravir/cobicistat and dolutegravir (adjusted relative hazard = 1.94 for elvitegravir/cobicistat versus dolutegravir, 95% CI = 1.00-3.76, P = 0.05). Conclusions In our real-life setting, INSTI-based regimens showed high potency and durability. Among regimens currently recommended in Europe, those including dolutegravir are associated with a lower risk of treatment failure.

Published
2018

120. Epidemiologia delle farmacoresistenze di HIV nella regione Sicilia

Author

Micali, C., Venanzi Rullo, E., Ceccarelli, M., D’Andrea, F., Lo Presti Costantino, M. R., Facciolà, A., Visalli, G., Picerno, I., Mondello, L., Guarneri, L., Scifo, G., Iacobello, C., Montineri, A., Cacopardo, B., Cascio, A., Amato, S., Foti, G., Farinella, E. M., Panella, L., Davì, A., Catania, V., Nunnari, G., and Pellicanò, G. F.

Published
2018

121. Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA project

Author

Bagella, P., De Socio, Gvl., Ricci, E., Menzaghi, B., Martinelli, C., Squillace, N., Maggi, P., Orofino, G., Calza, L., Carenzi, L., Belesia, B. M., Penco, G., Di Biagio, A., Valsecchi, L., Vichi, F., Colombo, V., Parruti, G., Dentone, C., Falasca, K., Bonfanti, P., Madeddu, G., Study Group Italy, On behalf of the C. I. S. A. I., Nunnari, G., Pellicano', Giovanni Francesco, Bagella, P, De Socio, G, Ricci, E, Menzaghi, B, Martinelli, C, Squillace, N, Maggi, P, Orofino, G, Calza, L, Carenzi, L, Celesia, B, Penco, G, Di Biagio, A, Valsecchi, L, Vichi, F, Colombo, V, Parruti, G, Dentone, C, Falasca, K, Bonfanti, P, Madeddu, G, Bagella, Paola, De Socio, Giuseppe V. L., Ricci, Elena, Menzaghi, Barbara, Martinelli, Canio, Squillace, Nicola, Maggi, Paolo, Orofino, Giancarlo, Calza, Leonardo, Carenzi, Laura, Celesia, Benedetto Maurizio, Penco, Giovanni, Di Biagio, Antonio, Valsecchi, Laura, Vichi, Francesca, Colombo, Valeria, Parruti, Giustino, Dentone, Chiara, Falasca, Katia, Bonfanti, Paolo, and Madeddu, Giordano

Subjects
0301 basic medicine, safety, Combination antiretroviral therapy, NNRTI, medicine.medical_specialty, Cohort study, Experienced patients, HIV-1, Naive, efficacy, Infectious Disease, Experienced patient, Gastroenterology, lcsh:Infectious and parasitic diseases, rilpivirine, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Median follow-up, Internal medicine, medicine, Pharmacology (medical), lcsh:RC109-216, 030212 general & internal medicine, Adverse effect, HIV-1, combination antiretroviral therapy, NNRTI, cohort study, naive, experienced patients, Original Research, Pharmacology, medicine.diagnostic_test, business.industry, 030112 virology, Antiretroviral therapy, Discontinuation, combination antiretroviral therapy, Infectious Diseases, Tolerability, chemistry, Infection and Drug Resistance, Rilpivirine, Lipid profile, business
Abstract

Paola Bagella,1 Giuseppe VL De Socio,2 Elena Ricci,3 Barbara Menzaghi,4 Canio Martinelli,5 Nicola Squillace,6 Paolo Maggi,7 Giancarlo Orofino,8 Leonardo Calza,9 Laura Carenzi,3 Benedetto Maurizio Celesia,10 Giovanni Penco,11 Antonio Di Biagio,12 Laura Valsecchi,3 Francesca Vichi,13 Valeria Colombo,14 Giustino Parruti,15 Chiara Dentone,16 Katia Falasca,17 Paolo Bonfanti,18 Giordano Madeddu1 On behalf of the C.I.S.A.I. Study Group, Italy 1Unit of Infectious Diseases, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy; 2Infectious Diseases Unit, Department of Medicine, Azienda Ospedaliero-Universitaria di Perugia, Santa Maria Hospital, Perugia, Italy; 3Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy; 4Unit of Infectious Diseases, ASST della Valle Olona, Busto Arsizio, Italy; 5Unit of Infectious and Tropical Diseases, Careggi Hospital Florence, Florence, Italy; 6Infectious Diseases Unit, San Gerardo Hospital, University of Milano-Bicocca, Monza, Italy; 7Infectious Diseases Clinic, University of Bari, Policlinico Consorziale, Bari, Italy; 8Amedeo di Savoia Hospital Unit of Infectious Diseases, Torino, Italy; 9University of Bologna, Department of Infectious Diseases, S. Orsola Malpighi Hospital, Bologna, Italy; 10Unit of Infectious Diseases, Garibaldi Hospital, Catania, Italy; 11Infectious Diseases Unit, Galliera Hospital, Genoa, Italy; 12Unit of Infectious Diseases, IRCCS San Martino Hospital – IST, Genoa, Italy; 13Infectious Diseases Unit, Santa Maria Annunziata Hospital, Florence, Italy; 14Infectious Diseases Unit, University of Milan, DIBIC Luigi Sacco, Milan, Italy; 15Unit of Infectious Diseases, Pescara Hospital, Pescara, Italy; 16Unit of Infectious Diseases, Sanremo Hospital, Sanremo, Italy; 17Infectious Diseases Unit, University of Chieti, Chieti, Italy; 18Unit of Infectious Diseases, A. Manzoni Hospital, Lecco, Italy Abstract: Rilpivirine is associated with a good efficacy and safety profile. However, data from real-life settings are scarce. Methods: We investigated the durability, safety and efficacy of Rilpivirine-based antiretroviral therapy in a prospective, observational, multicenter study. Results: We enrolled 499 HIV-infected patients, 360 (72.1%) males, mean age 43.4 ± 10.5years, mean CD4 600 ± 327 cell/μL, mean HIV-RNA 3.80 ± 1.15 log10 cp/mL. After a median follow up of 16 months, 81 (16.2%) interruptions were reported, 36 (7.2%) of which for adverse events (16 of grade ≥3), most commonly neurological and gastrointestinal. We observed virological failures in only 8 (1.6%) patients. Naive patients showed a significant reduction in eGFR at week 24, 48 and 72 and in total cholesterol (TC)/HDL ratio at week 48 (p=0.007). In patients switching from PI we found a significant decrease at week 24 and 48 in TC and triglycerides at week 24, 48 and 72. eGFR showed a significant decrease at week 48 and 72. TC/HDL ratio showed a statistically significant decrease at week 24 (p=0.0008) and 72 (p=0.04). A significant increase at week 24 and 48 in AST and ALT values was observed. Patients switching from TDF/FTC/EFV showed a reduction in HDL, total cholesterol and triglycerides at week 24 and 48 and in eGFR at all follow up times. TC/HDL ratio showed a significant decrease at week 48 (p=0.01). CDC stage C and antiretroviral-experience (especially Protease Inhibitors) were associated with RPV discontinuation. Conclusion: In conclusion, our data confirm Rilpivirine efficacy, safety and tolerability with improvement in lipid profile. Although hepatic and renal events rarely caused discontinuation, liver and kidney parameters should be monitored. Keywords: HIV-1, combination antiretroviral therapy, NNRTI, cohort study, naive, experienced patients

Published
2018

123. New and old assumptions of lung cancer in people living with HIV

Author

D’Aleo, F., Cama, B. A. V., Paolucci, I. A., VENANZI RULLO, E., Condorelli, F., Facciolà, A., DI FRANCIA, R., Savasta, A., Pinzone, M. R., Picerno, I., Visalli, G., Nunnari, G., Pellicanò, G. F., and Ceccarelli, M.

Subjects
Markers, Screening, HIV, Therapy, Lung cancer, Lung cancer, HIV, Screening, Therapy, Markers
Published
2018

126. Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients

Author

Dentone, C., Di Biagio, A., Cozzi Lepri, A., Fenoglio, D., Filaci, G., Lichtner, M., Carrara, S., Giacometti, A., Sighinolfi, L., Marchetti, G., Antinori, A., D’Arminio Monforte, A., Nunnari, G., Pellicano', Giovanni Francesco, Dentone, C., Di Biagio, A., Cozzi Lepri, A., Fenoglio, D., Filaci, G., Lichtner, M., Carrara, S., Giacometti, A., Sighinolfi, L., Marchetti, G., Antinori, A., D'arminio Monforte, A., and ICONA Foundation Study, Group, and Castagna, Antonella

Subjects
0301 basic medicine, Male, Vascular inflammation, activation markers,first-line antiretroviral therapy, atazanavir, darunavir, HIV, darunavir, HIV Infections, Gastroenterology, Therapy naive, 0302 clinical medicine, immune system diseases, heterocyclic compounds, Pharmacology (medical), activation markers, 030212 general & internal medicine, Prospective Studies, Prospective cohort study, atazanavir, Vascular inflammation, Darunavir, Confounding, virus diseases, Middle Aged, first-line antiretroviral therapy, Infectious Diseases, Combination, Drug Therapy, Combination, Female, medicine.drug, Adult, medicine.medical_specialty, Anti-HIV Agents, HIV, Atazanavir Sulfate, Biomarkers, Humans, Inflammation, Ritonavir, HIV-1, Emtricitabine, NO, 03 medical and health sciences, Drug Therapy, Internal medicine, parasitic diseases, medicine, business.industry, biochemical phenomena, metabolism, and nutrition, 030112 virology, Atazanavir, Regimen, business
Abstract

Background: Limited studies have compared the impact of different antiretroviral regimens on soluble markers of inflammation with discordant results. Methods: In this prospective study, treatment naïve HIV-1-infected patients were included if they started their current regimen with atazanavir/ritonavir (ATV/r) (N = 73, Group 1) or darunavir/ritonavir (DRV/r) (N = 85, Group 2) plus tenofovir/emtricitabine. The analysis of IL-6, MCP-1, sCD163, VCAM-1, ox-LDL, and adiponectine was performed on two stored plasma samples, the first prior to antiretroviral therapy initiation and the second one year after initiation. Results: The results of our analysis show a difference in ox-LDL between the two groups with higher mean (SD) values in ATV/r based group 608.5 ± 137.4 versus 519.1 ± 119.6 in DRV/r group, after controlling for baseline levels of ox-LDL as well as other potential confounding factors controlled by means of matching design or linear regression modelling. Conclusions: Our analysis provides further data examining the association between the modulation of vascular inflammatory and of activation markers with specific protease inhibitors-based treatments over one year of exposure to these drugs. The data show little evidence for an association, supporting the notion that antiretroviral regimens has generally poor efficiency in downregulating these soluble markers.

Published
2018

127. Hepatitis delta infection in patients with HIV/HBV coinfection

Author

Gaeta, G. B., Shanyinde, M., Brancaccio, G., Puoti, M., D’Arminio Monforte, A., De Luca, A., Vergori, A., Rusconi, S., Mazzarelli, A., Castagna, A., Antinori, A., Cozzi-Lepri, A., Nunnari, G., and Pellicano', Giovanni Francesco

Published
2018

134. Genotype 3 Infection in HIV/HCV co-infected subjects in the DAA era: Real life data from the ICONA/HepaICONA Foundation cohorts

Author

Rossotti, R., Lorenzini, P., Merli, M., Castagna, A., De Luca, A., Antinori, A., Chiamenti, M., Mastrorosa, I., Verucchi, G., Maggiolo, F., Monforte, A. D., Puoti, M., Nunnari, G., Pellicanò, G. F., Rossotti, R., Lorenzini, P., Merli, M., Castagna, A., De Luca, A., Antinori, A., Chiamenti, M., Mastrorosa, I., Verucchi, G., Maggiolo, F., Monforte, A. D., and Puoti, M.

Subjects
Hepatology, business.industry, Genotype, Medicine, Foundation (evidence), business, Real life data, Virology
Published
2018

135. Evolution of HIV-1 transmitted drug resistance in Italy in the 2007–2014 period: A weighted analysis

Author

Franzetti, M., De Luca, A., Ceccherini-Silberstein, F., Spagnuolo, V., Nicastri, E., Mussini, C., Antinori, A., Monno, L., Vecchiet, J., Fanti, I., D’Arminio Monforte, A., Balotta, C., Nunnari, G., G. F. Pellicanò., Franzetti, M., De Luca, A., Ceccherini-Silberstein, F., Spagnuolo, V., Nicastri, E., Mussini, C., Antinori, A., Monno, L., Vecchiet, J., Fanti, I., d'Arminio Monforte, A., and Balotta, C.

Subjects
0301 basic medicine, Adult, Male, Time Factors, Transmitted resistance, Genotype, Anti-HIV Agents, 030106 microbiology, Human immunodeficiency virus (HIV), Drug Resistance, HIV Infections, Drug resistance, medicine.disease_cause, Therapy naive, 03 medical and health sciences, Young Adult, Acquired resistance, Antiretroviral resistance, Spatio-Temporal Analysis, Risk Factors, Virology, HIV infection, Weighted analysis, Infectious Diseases, Drug Resistance, Viral, HIV Seropositivity, Prevalence, Medicine, Humans, Viral, Longitudinal Studies, Weighted analysi, Sexual risk, Retrospective Studies, Time trends, business.industry, Middle Aged, Settore MED/07 - Microbiologia e Microbiologia Clinica, Female, HIV-1, Homogeneous, Cohort, business, Demography
Abstract

Background Recent studies suggest that transmitted drug resistance (TDR) may be decreasing in latest years, likely because of the reduced frequency of acquired resistance. However, specific risk factors, geographical areas and special HIV-infected populations may be disproportionally affected by TDR. Objectives Correlates of TDR and time trends were evaluated from 2007 to 2014. Study design We evaluated the genotypic results of 2155 naive patients enrolled in the I.Co.N.A cohort at 23 clinical Centers in Italy between 2007 and 2014. A weighted analysis was performed to account for the patients enrolled in the cohort in each clinical Centre at each biennium (total number of patients: 3737). Results Overall prevalence of TDR was 10.7%. Independent predictors of TDR were sexual risk factor (OR 2.315, p = 0.020) and non-Italian geographical origin (OR 1.57, p = 0.038). The weighted prevalence of TDR was 10.5% with a stable proportion over calendar years. Generally, TDR prevalence was numerically higher, although not significantly, in clinical Centers of metropolitan areas with more than 3 millions of residents as compared to others (11.3% vs. 9.2%). The difference in TDR prevalence between these Centers decreased in more recent years. Conclusions A stable frequency of TDR was observed during the most recent years in Italy, with opposite and converging trends in large metropolitan areas as compared to the rest of the country, suggesting a more homogeneous spread of TDR across the country in latest years. Concerns remain for sexual route of infection and non-Italian origin, reinforcing the need for specific prevention strategies prioritizing specific populations.

Published
2018

142. Use of TAF with a HIV-RNA <50 cp/mL in clinical practice

Author

Lepri, A. Cozzi., Zaccarelli, M., Capetti, A., De Luca, A., Castagna, A., Bernacchia, D., Bai, F., Cingolani, A., Mussini, C., Perno, C. F., D’Arminio Monforte, A., Antinori, A., Nunnari, G., and Pellicano', Giovanni Francesco

Published
2018

146. Longitudinal proviral sequencing provides a window into selection pressures exerted on infected cells and provides an upper bound estimate of proviral half-lives which are influenced by expression and splicing potential

Author

Cannon, L., primary, Weissman, S., additional, Pinzone, M., additional, Van Belzen, J., additional, Venanzi-Rullo, E., additional, Ceccarelli, M., additional, Bertuccio, M.P., additional, Nunnari, G., additional, and O’Doherty, U., additional

Published
2019
Full Text
View/download PDF

149. Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART

Author

Ceccherini-Silberstein, F., Cozzi Lepri, A., Alteri, C., Merlini, E., Surdo, M., Marchetti, G., Capobianchi, M. R., De Luca, Andrea, Gianotti, N., Viale, P., Andreoni, M., Antinori, A., Perno, C. F., D'Arminio Monforte, A., Castagna, A., Castelli, F., Cauda, Roberto, Di Perri, G., Galli, M., Iardino, R., Ippolito, G., Lazzarin, A., Marchetti, G. C., Rezza, G., Von Schloesser, F., Cozzi-Lepri, A., Girardi, E., Lo Caputo, S., Mussini, C., Puoti, M., Ammassari, A., Balotta, C., Bandera, A., Bonfanti, P., Bonora, S., Borderi, M., Calcagno, A., Calza, L., Cingolani, Antonella, Cinque, P., Di Biagio, A., Gori, A., Guaraldi, G., Lapadula, G., Lichtner, M., Madeddu, G., Maggiolo, F., Marcotullio, S., Monno, L., Nozza, S., Quiros Roldan, E., Rossotti, R., Rusconi, S., Santoro, M. M., Saracino, A., Zaccarelli, M., Fanti, I., Galli, L., Lorenzini, P., Rodano, A., Shanyinde, M., Tavelli, A., Carletti, F., Carrara, S., Di Caro, A., Graziano, S., Petrone, F., Prota, G., Quartu, S., Truffa, S., Giacometti, A., Costantini, A., Barocci, V., Angarano, G., Santoro, C., Suardi, C., Donati, V., Verucchi, G., Minardi, C., Quirino, T., Abeli, C., Manconi, P. E., Piano, P., Cacopardo, B., Celesia, B., Vecchiet, J., Falasca, K., Sighinolfi, L., Segala, D., Blanc, P., Vichi, F., Cassola, G., Viscoli, C., Alessandrini, A., Bobbio, N., Mazzarello, G., Mastroianni, C., Pozzetto, I., Molteni, C., Chiodera, A., Milini, P., Nunnari, G., Pellicano, G., Rizzardini, G., Moioli, M. C., Piolini, R., Ridolfo, A. L., Salpietro, S., Tincati, C., Puzzolante, C., Chirianni, A., Borgia, G., Esposito, V., Orlando, R., Bonadies, G., Di Martino, F., Gentile, I., Maddaloni, L., Cattelan, A. M., Marinello, S., Cascio, A., Colomba, C., Baldelli, F., Schiaroli, E., Parruti, G., Sozio, F., Magnani, G., Ursitti, M. A., Acinapura, R., Baldin, G., Capozzi, M., Cicalini, S., Cristaudo, A., Fontanelli Sulekova, L., Iaiani, G., Latini, A., Mastrorosa, I., Plazzi, M. M., Savinelli, S., Vergori, A., Vullo, V., Cecchetto, M., Viviani, F., Bagella, P., Rossetti, Barbara, Franco, A., Fontana Del Vecchio, R., Francisci, D., Di Giuli, C., Caramello, P., Orofino, G. C., Sciandra, M., Bassetti, M., Londero, A., Pellizzer, G., Manfrin, V., Starnini, G., Ialungo, A., De Luca A. (ORCID:0000-0002-8311-6935), Cauda R. (ORCID:0000-0002-1498-4229), Cingolani A. (ORCID:0000-0002-3793-2755), Rossetti B., Ceccherini-Silberstein, F., Cozzi Lepri, A., Alteri, C., Merlini, E., Surdo, M., Marchetti, G., Capobianchi, M. R., De Luca, Andrea, Gianotti, N., Viale, P., Andreoni, M., Antinori, A., Perno, C. F., D'Arminio Monforte, A., Castagna, A., Castelli, F., Cauda, Roberto, Di Perri, G., Galli, M., Iardino, R., Ippolito, G., Lazzarin, A., Marchetti, G. C., Rezza, G., Von Schloesser, F., Cozzi-Lepri, A., Girardi, E., Lo Caputo, S., Mussini, C., Puoti, M., Ammassari, A., Balotta, C., Bandera, A., Bonfanti, P., Bonora, S., Borderi, M., Calcagno, A., Calza, L., Cingolani, Antonella, Cinque, P., Di Biagio, A., Gori, A., Guaraldi, G., Lapadula, G., Lichtner, M., Madeddu, G., Maggiolo, F., Marcotullio, S., Monno, L., Nozza, S., Quiros Roldan, E., Rossotti, R., Rusconi, S., Santoro, M. M., Saracino, A., Zaccarelli, M., Fanti, I., Galli, L., Lorenzini, P., Rodano, A., Shanyinde, M., Tavelli, A., Carletti, F., Carrara, S., Di Caro, A., Graziano, S., Petrone, F., Prota, G., Quartu, S., Truffa, S., Giacometti, A., Costantini, A., Barocci, V., Angarano, G., Santoro, C., Suardi, C., Donati, V., Verucchi, G., Minardi, C., Quirino, T., Abeli, C., Manconi, P. E., Piano, P., Cacopardo, B., Celesia, B., Vecchiet, J., Falasca, K., Sighinolfi, L., Segala, D., Blanc, P., Vichi, F., Cassola, G., Viscoli, C., Alessandrini, A., Bobbio, N., Mazzarello, G., Mastroianni, C., Pozzetto, I., Molteni, C., Chiodera, A., Milini, P., Nunnari, G., Pellicano, G., Rizzardini, G., Moioli, M. C., Piolini, R., Ridolfo, A. L., Salpietro, S., Tincati, C., Puzzolante, C., Chirianni, A., Borgia, G., Esposito, V., Orlando, R., Bonadies, G., Di Martino, F., Gentile, I., Maddaloni, L., Cattelan, A. M., Marinello, S., Cascio, A., Colomba, C., Baldelli, F., Schiaroli, E., Parruti, G., Sozio, F., Magnani, G., Ursitti, M. A., Acinapura, R., Baldin, G., Capozzi, M., Cicalini, S., Cristaudo, A., Fontanelli Sulekova, L., Iaiani, G., Latini, A., Mastrorosa, I., Plazzi, M. M., Savinelli, S., Vergori, A., Vullo, V., Cecchetto, M., Viviani, F., Bagella, P., Rossetti, Barbara, Franco, A., Fontana Del Vecchio, R., Francisci, D., Di Giuli, C., Caramello, P., Orofino, G. C., Sciandra, M., Bassetti, M., Londero, A., Pellizzer, G., Manfrin, V., Starnini, G., Ialungo, A., De Luca A. (ORCID:0000-0002-8311-6935), Cauda R. (ORCID:0000-0002-1498-4229), Cingolani A. (ORCID:0000-0002-3793-2755), and Rossetti B.

Abstract

Objectives We evaluated the association between pre-ART HIV DNA and HIV-infected participant characteristics at baseline as well as with their response to first-line ART. Methods Four hundred and thirty-three patients from the ICONA cohort, starting first-line ART after the year 2000, were analysed. Pre-ART HIV DNA was quantified with the modified COBAS TaqMan HIV-1 Test and normalized by CD4+ T cells. Linear correlation between pre-ART HIV DNA and other continuous markers (HIV RNA, CD4 count, markers of inflammation and coagulation) at baseline was evaluated by means of Pearson correlation coefficient and a linear regression model. Survival analyses and Cox regression models were used to study the association between pre-ART HIV DNA and time to VIRO-immunoclinical events. Results Pre-ART HIV DNA [median (IQR): 10 € 702 (3397-36 € 632) copies/10 6 CD4+ T cells] was correlated with pre-ART HIV RNA [R 2 = +0.44, (P < 0.0001)], CD4+ T cells [R 2 = '0.58, (P < 0.0001)] and CD4/CD8 ratio [R 2 = '0.48, (P < 0.0001)], while weaker correlations were observed with CD8+ T cells (R 2 = '0.20, P = 0.01), IL-6 (R 2 = +0.16, P = 0.002) and soluble CD14 (R 2 = +0.09, P = 0.05). Patients with higher pre-ART HIV DNA showed lower rate and delayed VIROlogical response (defined as HIV RNA ≤50 copies/mL), compared with those having lower HIV DNA (67.2% for >10 € 000, 81.1% for 1000-10 € 000 and 86.4% for 10-1000 copies/10 6 CD4+ T cells; P = 0.0004). Higher pre-ART HIV DNA was also correlated with increased risk of VIROlogical rebound (defined as HIV RNA >50 copies/mL) by 24 months (17.2% for >10 € 000, 7.4% for 1000-10 € 000 and 4.3% for 10-1000 copies/10 6 CD4+ T cells; P = 0.0048). Adjusted HRs of all VIROlogical rebound definitions confirmed these findings (P ≤ 0.02). Conclusions Pre-ART HIV DNA, along with HIV RNA and CD4+ T cell count, should be considered as a new staging marker to better identify people at lower (or higher) risk of viral rebound following achie

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results